OIS@AAO 2019

Henry Hsu, MD, and CEO of Allysta Pharma, talks about the unmet needs of dry eye and ALY688’s promise for treating symptoms of the disease…

Bausch + Lomb’s Calvin Roberts, MD, discusses the success the company has had over the past year, including the rapid market acceptance of Lumify, Lotemax…

Michael Mrochen, President speaks for Allotears during the Innovative Showcase at OIS@AAO 2019. REGISTER for our next ophthalmology conference today http://bit.ly/2yFA6cv.

Aerpio’s Kevin Peters, MD, discusses how his company’s lead VE-PTP inhibitor/Tie2 activator AKB-9778 enhances both vascular stability and fluid outflow, making it a potential candidate…

Allegro’s Vicken Karageozian, MD, talks about the risuteganib phase 2 for intermediate dry AMD (showing a “robust reversal of vision loss”), their dry eye drug…

Glenn Sblendorio, CEO & President, speaks about IVERIC bio’s plans to develop gene therapies for orphan inherited retinal diseases. Plans include a phase 1/2 in…

Ken Mills, CEO speaks for REGENXBIO during the Public Company Spotlight at OIS@AAO 2019. REGISTER for our next ophthalmology conference today http://bit.ly/2yFA6cv.

 Megan Baldwin, PhD, CEO & Managing Director speaks for OPTHEA during the Public Company Spotlight at OIS@AAO 2019. REGISTER for our next ophthalmology conference…